Trial reportThe British journal of dermatology2015
A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone.
Trial report in The British journal of dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00283712 (A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Infliximab in Subjects With Pemphigus Vulgaris Receiving Prednisone), which is not on this map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Infliximab in Subjects With Pemphigus Vulgaris Receiving Prednisone
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- A systematic review of therapeutic and paradoxical roles of tumor necrosis factor α inhibitors in autoimmune blistering diseases.Inflammopharmacology · 2026Pooled it
- World Workshop of Oral Medicine VII: A systematic review of immunobiologic therapy for oral manifestations of pemphigoid and pemphigus.Oral diseases · 2019Pooled it
- Research Progress on Targeted Therapies for Pemphigus Vulgaris and Bullous Pemphigoid: Mechanisms, Opportunities and Challenges.International journal of molecular sciences · 2026Review
- Treatment of Autoimmune Bullous Diseases During Pregnancy and Lactation: A Review Focusing on Pemphigus and Pemphigoid Gestationis.Frontiers in pharmacology · 2020Review
- Pemphigus Vulgaris: Short Time to Relapse in Patients Treated in a Danish Tertiary Referral Center.Frontiers in medicine · 2019Article
- RemicadeBiologics : targets & therapy · 2019Review
- Emerging treatment options for the management of pemphigus vulgaris.Therapeutics and clinical risk management · 2018Review
- Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis.PloS one · 2018Article
- Analysis of Serum Cytokine Profile in Pemphigus.Annals of dermatology · 2017Article
- Increased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with Pemphigus.PloS one · 2016Article
- The continuing evolution of targeted therapy for inflammatory skin disease.Seminars in immunopathology · 2016Review
- [Pemphigus. Model disease for targeted therapy].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2015Review
- Prediction of survival for patients with pemphigus vulgaris and pemphigus foliaceus: a retrospective cohort study.Orphanet journal of rare diseases · 2015Article
- Management of pemphigus vulgaris: challenges and solutions.Clinical, cosmetic and investigational dermatology · 2015Review
- Shifting Focus in the Therapeutics of Immunobullous Disease.Indian journal of dermatologyArticle
Corrections and comments
- Commented on by
Authors and funding
15 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundPemphigus vulgaris (PV) is a blistering disease and tumour necrosis factor-α has a role in its pathogenesis.
objectivesTo evaluate the safety of infliximab (IFX) with prednisone compared with prednisone alone in the treatment of PV. In addition, treatment response was assessed and mechanistic studies were performed.
methodsSubjects with PV who had ongoing disease activity while being maintained on prednisone were randomized to receive either IFX or placebo in addition to prednisone. Response status and immunoglobulin (Ig) G anti-desmoglein (Dsg)1 and Dsg3 antibodies were assessed at 18 and 26 weeks.
resultsTen subjects were randomized to each group. There were no safety signals during the course of the study. At week 18, one subject in each group had responded. At week 26, three IFX-treated subjects vs. none in the placebo group had responded (P = 0·21). At weeks 18 and 26, the median IgG anti-Dsg1 and anti-Dsg3 levels were lower in the IFX-treated patients [IgG anti-Dsg-1 (week 18, P = 0·035; week 26, P = 0·022); IgG anti-Dsg3 (week 18, P = 0·035; week, 26 P = 0·05)].
conclusionsThis study is limited by the relatively small sample size. There was no significant difference between study arms in the proportion of subjects with treatment-related adverse events > grade 3. IFX therapy was not shown to be effective for the treatment of patients with PV in this randomized, placebo-controlled trial, although IFX treatment may be associated with a decrease in anti-Dsg1 and Dsg3 antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.